The EPO published patent EP3993810A1 titled 'Inhalable Composition Comprising Cyclodextrin for Use in the Treatment of Nasal Inflammations' filed by Aquilon Pharmaceuticals. The composition utilizes cyclodextrin (A61K 31/724) as the active pharmaceutical ingredient delivered via inhalation for nasal inflammation treatment (A61P 11/02). The patent was published on March 25, 2026.

This is a patent publication notice rather than a regulatory requirement. Pharmaceutical companies developing nasal delivery systems or cyclodextrin-based therapeutics should review the patent claims to assess potential freedom-to-operate implications. Drug manufacturers exploring anti-inflammatory nasal treatments may need to design around these claims or seek licensing arrangements with Aquilon Pharmaceuticals.